UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.
Researchers at UC San Diego have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs. The discovery opens the possibility of new therapies, including for multiple forms of cancer.
Building upon a long history, the UC San Diego has launched a new Human Milk Institute to accelerate research into the biology and therapeutic potential of human milk to prevent or treat both infant and adult diseases. The new institute is believed to be the first of its kind in the United States.
Using a novel systems biology approach, scientists at UC San Diego School of Medicine have further parsed the cellular players and roles involved in rheumatoid arthritis, a complex disease that affects more than one million Americans in ways that have defied development of uniform treatments.
During October’s Breast Cancer Awareness Month, a breast cancer survivor and UC San Diego Health employee shares her personal experiences from the moment of diagnosis and receiving life-saving care, to the important lessons she has learned along the journey.
UC San Diego Health is now offering a new treatment for patients with low-grade upper tract urothelial cancer that could safely avoid removal of the entire kidney, which may prevent the need for dialysis or kidney transplant in the future.
Forbes, May 29
San Diego Union Tribune, May 28
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
